496 related articles for article (PubMed ID: 26723242)
1. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Li BT; Ross DS; Aisner DL; Chaft JE; Hsu M; Kako SL; Kris MG; Varella-Garcia M; Arcila ME
J Thorac Oncol; 2016 Mar; 11(3):414-9. PubMed ID: 26723242
[TBL] [Abstract][Full Text] [Related]
2. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
3. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
[TBL] [Abstract][Full Text] [Related]
5. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
Rossi E; Villanacci V; Danesino C; Donato F; Nascimbeni R; Bassotti G
Rev Esp Enferm Dig; 2011 Dec; 103(12):632-9. PubMed ID: 22217347
[TBL] [Abstract][Full Text] [Related]
7. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
Li BT; Lee A; O'Toole S; Cooper W; Yu B; Chaft JE; Arcila ME; Kris MG; Pavlakis N
Lung Cancer; 2015 Dec; 90(3):617-9. PubMed ID: 26559459
[TBL] [Abstract][Full Text] [Related]
8. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
10. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
Cancer; 2017 Nov; 123(21):4099-4105. PubMed ID: 28743157
[TBL] [Abstract][Full Text] [Related]
11. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
[TBL] [Abstract][Full Text] [Related]
15. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
17. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.
Pala EE; Bayol U; Keskin EU; Ozguzer A; Kucuk U; Ozer O; Koc A
Pathol Oncol Res; 2015 Sep; 21(4):1223-7. PubMed ID: 26060045
[TBL] [Abstract][Full Text] [Related]
18. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
19. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
